Specifications

Specificity: Th1 response

Working concentration: 10- 100 μg/mouse

Solubility: 1 mg/ml in physiological water

Documents

• TDS Gardiquimod VacciGrade : 5 mg (vac-gdq)
• MSDS Gardiquimod VacciGrade : 5 mg (vac-gdq)

Contents

• 5 mg of sterile lyophilized Gardiquimod VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Gardiquimod VacciGrade™ is shipped at room temperature and should be stored at -20°C. Lyophilized product is stable 1 year when properly stored. Upon resuspension, prepare aliquots of Gardiiquimod VacciGrade™ and store at -20°C for long term storage. Resuspended product is stable 6 months when properly stored. Avoid repeated freeze-thaw cycles.

Description

Gardiquimod™ is a imidazoquinoline compound developed and manufactured by InvivoGen. Similarly to Imiquimod, Gardiquimod™ induces the activation of NF-κB in HEK293 cells expressing human or mouse TLR7. In vitro models of vaccination indicate that Gardiquimod™ is a strong immunostimulant inducing cytokine production and the generation of dendritic cells [1].

Experimental models demonstrated that Gardiquimod™ can induce strong cellular responses and has potential as an adjuvant for cancer therapy [2, 3]. Furthermore, Gardiquimod™ can induce mucosal responses that are superior to R848 and comparable to those induced by the established mucosal adjuvant cholera toxin [4].

1. Ma Y et al., 2007. In vitro vaccination site: a novel test bed for immunopotentiators. J Immunol. 178, S18.
2 Ma F. et al., 2010. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cellular & Molecular Immunology 7, 381-388.
3. Cho HI & Celis E., 2009. Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects. Cancer Res. 69(23):9012-9. 4. Velasquez LS. et al., 2010. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol. 17(12):1850-8.